Oxford Biomedica Solutions
Christopher Smith is a highly experienced Principal Scientist at Nvelop Therapeutics, specializing in method development for biochemical and biophysical characterization of gene therapy modalities since November 2023. Prior to this role, Christopher served as a Senior Scientist in Analytical Development at Oxford Biomedica, focusing on AAV capsid analysis, and held several positions at Homology Medicines, Inc., where expertise in analytical methods for AAV variants was developed. Christopher's background also includes analytical work at AbbVie, protein research at Enzo Life Sciences, and postdoctoral research at Northern Illinois University, complemented by a Ph.D. in Biochemistry and a Bachelor's degree in Biology from prestigious institutions.
This person is not in the org chart
Oxford Biomedica Solutions
Oxford Biomedica Solutions, LLC is the high-performing, full scope Adeno-Associated Virus (AAV) vector Manufacturing and Innovation joint venture of Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), and Homology Medicines, Inc. (Nasdaq: FIXX) (“Homology”). We offer global pharmaceutical and biotechnology clients innovative manufacturing expertise in AAV and lentiviral-based cell and gene therapies. Oxford Biomedica Solutions LLC provides access to Homology’s innovative and proven end-to-end AAV manufacturing capabilities, and customers also benefit from technical synergies brought in by the Group’s know-how in lentiviral vector manufacturing. This collaborative and complementary vector-based approach has the potential to accelerate our collective mission to improve patients’ lives worldwide.